Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04229888 · ClinicalTrials.gov registry record · NA
Meibomian Gland Dysfunction Treatment
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT04229888: Completed NA study, sponsored by Indiana University.
NCT04229888 is a NA study that has completed, run by Indiana University. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04229888, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of treatments for Meibomian Gland Dysfunction.
Primary Outcome
DEQ5 total score ranges from 0-22 with the higher scores indicating increased dry eye.
Interventions
- DEVICE LipiFlow
- DEVICE Light Based (Sham) Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2021-03-25 |
| Phase | NA |
What the finished NCT04229888 record still lists
NCT04229888 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which LipiFlow is the first listed.
NCT04229888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04229888 about?
NCT04229888 is a clinical study titled "Meibomian Gland Dysfunction Treatment". The purpose of this study is to evaluate the effectiveness of treatments for Meibomian Gland Dysfunction.
What is the current status of trial NCT04229888?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2020-02-26. Estimated completion is 2021-03-25.
What interventions are being tested in trial NCT04229888?
The interventions under investigation include: LipiFlow (DEVICE), Light Based (Sham) Treatment (DEVICE).
Who is sponsoring clinical trial NCT04229888?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04229888's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy